Treatment of sialorrhoea in patients with Parkinson's disease: best current evidence.
(1) Sialorrhoea is a common condition in patients with Parkinson's disease that has a negative impact on patient quality of life. (2) Traditionally, muscarinic antagonists have been the pharmacological agents of choice for the treatment of sialorrhoea; however, these agents are frequently associated with adverse events in patients with Parkinsonian disorders. (3) Recent studies suggest that botulinum toxin injection is currently the most effective treatment option for Parkinsonian-related sialorrhoea.
Molloy
Luke
L
Wolters Kluwer Health/Adis, Auckland, New Zealand.
D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D006801:Humans; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D009465:Neuromuscular Agents / Q000627:therapeutic use; D010300:Parkinson Disease / Q000150:complications / Q000503:physiopathology; D011788:Quality of Life; D012196:Review Literature as Topic; D012798:Sialorrhea / Q000188:drug therapy / Q000209:etiology; D016896:Treatment Outcome
D018727:Muscarinic Antagonists; D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A